Premium
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical t... Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.09 | -5.32544378698 | 1.69 | 1.83 | 1.56 | 156546 | 1.68295111 | CS |
| 4 | -0.65 | -28.8888888889 | 2.25 | 2.48 | 1.56 | 99414 | 1.84563038 | CS |
| 12 | -1 | -38.4615384615 | 2.6 | 3.12 | 1.56 | 95278 | 2.2830911 | CS |
| 26 | -1.6 | -50 | 3.2 | 4.72 | 1.56 | 85866 | 2.67814448 | CS |
| 52 | -58.37 | -97.331999333 | 59.97 | 59.97 | 1.56 | 97191 | 5.88029215 | CS |
| 156 | -58.37 | -97.331999333 | 59.97 | 59.97 | 1.56 | 32268 | 5.88029215 | CS |
| 260 | -58.37 | -97.331999333 | 59.97 | 59.97 | 1.56 | 21763 | 5.88029215 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
